Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy (TEE) with AS and RT for High-Risk Prostate Cancer
NCT00004054Phase 3Completed
- Sponsor
- NRG Oncology
- Start
- Jan 2000
- Primary completion
- Apr 2010
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of Paclitaxel Micelles for Injection, estramustine and etoposide in prostate cancer (PCa) (2 arms), sponsored by NRG Oncology. Primary endpoint: Overall Survival at 5 years. Started Jan 2000; status: completed.
02
Drugs
Paclitaxel Micelles for Injectionestramustineetoposide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00004054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004054.